# Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

Source: https://onco.cc/trials/nct06846606/  
OnCo record `nct06846606` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of AUTX-703 run by Auron Therapeutics, Inc., now recruiting.

## Summary

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS is a phase 1 interventional study registered as NCT06846606 by Auron Therapeutics, Inc., with 69 participants planned, started 2025-05-01. Conditions recorded: Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Relapsed/Refractory AML, Relapsed Myelodysplastic Syndromes, Refractory Myelodysplastic Syndromes and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). Interventions recorded: AUTX-703.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06846606
- Phase: 1
- Setting: A Phase 1 Study of AUTX-703 in Participants With Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Sponsor: Auron Therapeutics, Inc.
- Enrolled: 69

## Sources

- ClinicalTrials.gov NCT06846606: https://clinicaltrials.gov/study/NCT06846606

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- drugs: [AUTX-703](https://onco.cc/drugs/autx-703/)
- companies: [Auron Therapeutics](https://onco.cc/companies/auron-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06846606.json